Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | SMPD1 | P17405 | 6/20 | 0.48 |
| ▸ | MGLL | Q99685 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11887248 | 0.86 | THRA (0.55) | THRATHRBSMPD1ALDH1A1HPGD | |
| SCHEMBL6514520 | 0.84 | THRA (0.53) | THRATHRBSMPD1MGLLALDH1A1 | |
| SCHEMBL13557087 | 0.83 | THRA (0.47) | THRATHRBSMPD1ALDH1A1HPGD | |
| SCHEMBL11888422 | 0.81 | MAPT (0.51) | ALDH1A1HPGD | |
| SCHEMBL24950547 | 0.80 | SMPD1 (0.67) | THRATHRBSMPD1MGLLALDH1A1 | |
| SCHEMBL9565566 | 0.80 | SMPD1 (0.67) | THRATHRBSMPD1MGLLALDH1A1 | |
| SCHEMBL9304902 | 0.80 | SMPD1 (0.67) | THRATHRBSMPD1MGLLALDH1A1 | |
| SCHEMBL967401 | 0.80 | SMPD1 (0.67) | THRATHRBSMPD1MGLLALDH1A1 | |
| SCHEMBL9306905 | 0.79 | THRA (0.65) | THRATHRBSMPD1MGLL | |
| SCHEMBL9306887 | 0.79 | THRA (0.65) | THRATHRBSMPD1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910616-B2 | Proteasome inhibitors | NEREUS PHARMACEUTICALS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090298906-A1 | PROTEASOME INHIBITORS | NEREUS PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298906-A1 | PROTEASOME INHIBITORS | PSMB1, PSME1, PSME3 | THRA 4221/4885THRB 3496/4885SMPD1 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.